Prognostic factors in malignant pleural mesothelioma: A retrospective study of 60 Turkish patients

Clicks: 559
ID: 96925
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #8 of 148 articles by views in journal of cancer research and therapeutics

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 148 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Aim: Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis. The study aims to examine the effect of certain clinical, laboratory, radiologic, and pathologic characteristics on survival. Patients and Methods: Sixty patients who had undergone PET/CT evaluation at initial diagnosis were included. We investigated the effect of certain clinical, laboratory, radiologic characteristics, SUVmax of the tumor, and pathological characteristics such as histological subtype, mitotic activity index (MAI), tumor necrosis, and inflammation on survival. The pathological slides of each patient were re-evaluated for MAI, presence of necrosis, and inflammation. The patients were grouped based on number of mitosis as MAI 1:≤9, MAI 2:10-19, MAI 3: >19 mitosis. Results: There were 34 male and 26 female patients with a mean age of 53.6 ΁ 10.6 years. Mean and median survival time was 14.83 ΁ 10.75 and 11.95 (min 0.43-max 48.10) months, respectively. Using univariate analysis leukocytosis (P = 0.009), rind-like pleural thickening (P = 0.037), advanced disease stage (P = 0.004), best supportive therapy alone (P = 0.004), SUVmax higher than 8 (P = 0.023), MAI higher than 1 (P = 0.033), and presence of tumor necrosis (P = 0.037) were found as poor prognostic factors. At multivariate analysis, leukocytosis (P = 0.026, HR: 2.27), advanced disease stage (P = 0.021, HR: 2.46), best supportive therapy alone (P = 0.029, HR: 5.12), and MAI higher than 1 (P = 0.01, HR: 3.01) were independently associated with survival, whereas SUVmax of the tumor failed to enter the model (P = 0.07, HR: 1.89). Conclusion: Presence of leukocytosis, advanced disease stages, supportive therapy alone, and higher MAI were found to be negative prognostic factors in patients with MPM.
Reference Key
koyuncu2015prognosticjournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Koyuncu, Adem;Koksal, Deniz;Ozmen, Ozlem;Demirag, Funda;Bayiz, Hulya;Aydogdu, Koray;Berkoglu, Mine;
Journal journal of cancer research and therapeutics
Year 2015
DOI
DOI not found
URL
http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2015;volume=11;issue=1;spage=216;epage=222;aulast=Koyuncu
Keywords
Therapeutics. Pharmacology Veterinary medicine Medicine (General) Medicine otorhinolaryngology medical physics. medical radiology. nuclear medicine neoplasms. tumors. oncology. including cancer and carcinogens nutrition. foods and food supply diseases of the respiratory system diseases of the endocrine glands. clinical endocrinology internal medicine specialties of internal medicine

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.